Gentical Raises $23.7M From Wellington, EdRIP, InnoBio, Others

Wellington Partners said it is the lead investor in a $23.7 million Series C financing round for Genticel which was closed this week. Wellington Partners committed about $5 million and the remaining came from existing shareholders, including EdRIP, IDInvest, InnoBio, IRDI and Amundi. The funds will be used primarily to finance a phase II program for the Toulouse, France-based HPV- vaccine developer’s lead product ProCervix.

Genticel Raises €13.1 Million

Genticel (f.k.a. BT Pharma), a French developer of immunotherapies to prevent cancers caused by HPV, has raised €13.1 million in new VC funding. AGF Private Equity led the round, and was joined by the Institut Régional de Développement Industriel, Amundi Private Equity Funds, InnoBio fund (CDC Enterprises) and return backer Edmond de Rothschild Investment Partners.

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget